P

Poolbeg Pharma PLC
LSE:POLB

Watchlist Manager
Poolbeg Pharma PLC
LSE:POLB
Watchlist
Price: 7.105 GBX -0.63% Market Closed
Market Cap: 35.5m GBX
Have any thoughts about
Poolbeg Pharma PLC?
Write Note

Poolbeg Pharma PLC
Net Change in Cash

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Poolbeg Pharma PLC
Net Change in Cash Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Change in Cash CAGR 3Y CAGR 5Y CAGR 10Y
P
Poolbeg Pharma PLC
LSE:POLB
Net Change in Cash
-ÂŁ4m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
GlaxoSmithKline PLC
LSE:GSK
Net Change in Cash
-ÂŁ159m
CAGR 3-Years
67%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
AstraZeneca PLC
LSE:AZN
Net Change in Cash
$1.2B
CAGR 3-Years
-50%
CAGR 5-Years
-14%
CAGR 10-Years
N/A
Verona Pharma PLC
NASDAQ:VRNA
Net Change in Cash
$78.7m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Hikma Pharmaceuticals PLC
LSE:HIK
Net Change in Cash
-$36m
CAGR 3-Years
27%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Dechra Pharmaceuticals PLC
LSE:DPH
Net Change in Cash
-ÂŁ46.5m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Poolbeg Pharma PLC
Glance View

Market Cap
35.5m GBX
Industry
Pharmaceuticals

Poolbeg Pharma Plc is a clinical-stage infectious disease pharmaceutical company. The firm is focused on targeting the medical needs to treat and prevent infectious disease. The firm's portfolio includes POLB 001, Vaccine Discovery Platform, PredictViral Biomarker Platform, and disease progression data and bio banks. The firm's lead product pipeline candidate is POLB 001. POLB 001 is a Phase II ready p38 mitogen-activated protein kinase (MAPK) inhibitor that reduces harmful inflammation (cytokine storm) in patients with severe influenza. POLB 001 is a repositioned small molecule immunomodulator for severe influenza. The firm is developing a PredictViral biomarker platform, which is used to identify those at risk of developing severe disease. The Vaccine Discovery Platform is a platform used to identify vaccine candidates by isolating protective elements of the naturally occurring immune response.

POLB Intrinsic Value
2.434 GBX
Overvaluation 66%
Intrinsic Value
Price
P

See Also

What is Poolbeg Pharma PLC's Net Change in Cash?
Net Change in Cash
-4m GBP

Based on the financial report for Dec 31, 2023, Poolbeg Pharma PLC's Net Change in Cash amounts to -4m GBP.

What is Poolbeg Pharma PLC's Net Change in Cash growth rate?
Net Change in Cash CAGR 1Y
15%

Over the last year, the Net Change in Cash growth was 15%.

Back to Top